xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

378

International consensus statement on rhinosinusitis

(Continues)

Ig therapy does not appear to be effective in patients with CVID. For these patients, ESS is justified to restore mucociliary function and normal ventilation. Sethi 492 1995 4 Case series Patients with refractory recurrent RS and immunologic abnormalities; age 3-71; n = 20 Quantitative Ig levels Functional antipneumococcal antibody responses Immune defects may exist in a significant

IgG3 levels are significantly decreased in adults withCRS. Karlsson 942 1985 4 Case control 22 patients with CVID; 18 patients with selective IgA deficiency; 20 controls; age 22-58 Co-existence of CRS Incidence of sinus surgery

RARS may be the primary or only clinical manifestation of immunodeficiencies. The

diagnosis should be considered in any patient failing routine management.

percentage of patients with refractory CRS and RARS. Armenaka 933 1994 4 Case control 30 CRS matched to 30chronic rhinitis patients with normal CTs, and 30 healthy controls; age 16-75 Quantitative Ig levels IgG subclass levels

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Tahkokallio 938 2001 4 Case control 25 patients with severe RARS or CRSand matched controls; age 19-64 Serum IgA levels Pneumococcal antibodies Low serum IgA may be associated with a susceptibility to RS. May 955 1999 4 Case series CRS patients not responding to antibiotics; age 4-79; n = 245 Humoral antibody levels Pneumococcal antibody response

The development of CRS was only found in patients with CVID, indicating the more

severe nature of this condition compared with selective IgA deficiency. Manning 929 1994 4 Case series Patients with severe refractory RS and PID; age 27-59 Serum IgG subclass levels Pneumococcal vaccine responses Immunoglobulin A levels Response to Ig therapy

TABLE IX-18 (Continued)